Hyperglycaemia is a common finding in patients who are acutely ill even in the absence of a prior diagnosis of diabetes mellitus. In acutely ill patients, hyperglycaemia is associated with a worse outcome. As hyperglycaemia is consistently associated with increased morbidity and mortality, critical care researchers have conducted a number of trials to investigate whether tighter control of blood glucose in critically ill patients is beneficial. To date there have been over 30 randomised controlled trials of tight glucose control in critical care settings. However, many studies have reported non-significant results; in part this is because many of the trials were small and when considered alone had insufficient statistical power to examine the effects of tight glucose control on mortality. Aims The aim of this collaborative research project is to combine the individual patient data from all randomized controlled trials of tight glucose control in critically ill adults around the world to conduct

Project aims to develop an integrated, patient-centred, affordable and sustainable system for proactive management of patients undergoing peritoneal dialysis based on patients’ needs using innovative technologies and methodologies for service design Methods This is an observational cohort study which aims to develop a user-friendly and functional IT supported system for education and monitoring of patients undergoing peritoneal dialysis in their homes. We intend to collect information on physiological measures through different sensors in order to be able to compare and ascertain which methods are most acceptable to patients and providers. Study sites Postgraduate Institute of Medical Education and Research, Chandigarh and Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow. Current status The prototype Mobile Application is being tested

p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 15.0px Times; color: #323333; -webkit-text-stroke: #323333} p.p2 {margin: 0.0px 0.0px 0.0px 0.0px; font: 18.0px Arial; color: #323333; -webkit-text-stroke: #323333} span.s1 {font-kerning: none} span.s2 {text-decoration: underline ; font-kerning: none; color: #772583; -webkit-text-stroke: 0px #772583} span.s3 {font: 14.0px Calibri; font-kerning: none; color: #000000; -webkit-text-stroke: 0px #000000} span.s4 {font: 13.0px Calibri; font-kerning: none} span.s5 {font: 9.0px 'Times New Roman'; font-kerning: none} Fluid administration is a fundamental component of the management of critically ill patients and the choice of fluid is a longstanding issue of debate. Worldwide, 0.9% saline has traditionally been the most widely used resuscitation fluid, however its use is increasingly challenged by evidence that suggests its high chloride content may have clinically important adverse effects. Two pivotal George Institute trials, the Saline versus Albumin

A prospective, multicentre, parallel group, concealed, blinded, randomised controlled trial in critically ill mechanically-ventilated adults. The aim is: To determine whether the administration of placebo (daily administration of 10 ml 0.9% saline IV) is non-inferior to standard practice (daily administration of pantoprazole 40 mg IV) when judged by the incidence of clinically important gastrointestinal (GI) bleeding?  To determine whether the administration of placebo (daily administration of 10 ml 0.9% saline IV) is superior to standard practice (daily administration of pantoprazole 40 mg IV) as it results in a reduction in net harm by reducing the incidence of serious infectious complications (ventilator-associated pneumonia and Clostridium difficile infection) and therefore "downstream" harms when measured as duration of mechanical ventilation, intensive care unit (ICU) and hospital length of stay, and 90-day mortality? 

Current status– finished recruitment – in follow-up.TRIDENT is an international medical research study which aims to determine the effect of more intensive blood pressure control to prevent recurrent stroke in patients who have had an intracerebral haemorrhage (ICH) (a stroke caused by ruptured blood vessel in the brain). The aim of this project is to test the superiority of a fixed low-dose combination blood pressure-lowering pill (Triple Pill) strategy in recurrent stroke in patients with a history of ICH.Acute ICH accounts for at least 10% of the 20 million new strokes in the world each year. ICH survivors are at high risk of recurrent stroke and other serious cardiovascular events. Numerous studies have proven the benefit of stroke survivors reducing their risk of recurrent stroke through taking blood pressure-lowering medications. However, studies have shown that many ICH survivors are either not receiving any blood pressure-lowering medication or they are receiving inadequate control.The TRIDENT stu